drugset / Trial / NCT01407575
Buprenorphine for Treatment Resistant Depression
Phase 3
Completed
13 enrolled
University of Pittsburgh
National Alliance for Research on Schizophrenia and Depression · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to compare the safety and efficacy of buprenorphine with placebo for adults with treatment resistant depression (TRD).
Timeline
- Start
- 2011-09
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | 0.2 mg | Other |
| Subject | Buprenorphine | Other / unclassified | 1.6 mg | Other |